Search | IOVS | ARVO Journals

Showing 1 – 20 of 23

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Differences in Serious Difficulty Seeing and Utilization of Eye Exams by Sexual Orientation (2016-2020)

Kevin D Frick

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3384 – A0171.

Special Issue April 2021

IMI Impact of Myopia

PDF

Padmaja Sankaridurg; Nina Tahhan; Himal Kandel; Thomas Naduvilath; Haidong Zou; Kevin D. Frick; Srinivas Marmamula; David S. Friedman; Ecosse Lamoureux; Jill Keeffe; Jeffrey J. Walline; Timothy R. Fricke; Vilas Kovai; Serge Resnikoff
TAGS: myopia
Invest. Ophthalmol. Vis. Sci.. 2021; 62(5):2. https://doi.org/10.1167/iovs.62.5.2

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

Trends in eyecare access and affordability: The National Health Interview Survey (NHIS) 2008–2016

Varshini Varadaraj; Kevin D Frick; Jinan Saaddine; David S Friedman; Bonnielin K Swenor

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1598.

ARVO Annual Meeting Abstract July 2018

Cost analysis of a school-based vision program in Baltimore, MD

Alyssa M Kretz; Moneesha Rani Mukherjee; Niral B Ghandi; Robert Slavin; Nancy Madden; David S Friedman; Michael X Repka; Leana Wen; Gabriel Auteri; Evan Behrle; Kevin D Frick; Megan E Collins

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):181.

ARVO Annual Meeting Abstract June 2017

Estimated global productivity loss from myopia

Kovin Shunmugam Naidoo; Tim R Fricke; Padmaja Sankaridurg; Thomas Naduvilath; Serge Resnikoff; Kevin D Frick

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2404.

ARVO Annual Meeting Abstract June 2017

Overview of Surveillance Recommendations of the "Making Eye Health a Population Health Imperative: Vision for Tomorrow" Report, from the National Academies of Sciences, Engineering, and Medicine

Kevin D Frick

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4719.

ARVO Annual Meeting Abstract September 2016

Analysis of the cost savings from applying optical coherence tomography (OCT) to guide treatment for choroidal neovascularization

Kevin D Frick; Sissi Sun; David Huang

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5580.

ARVO Annual Meeting Abstract September 2016

Longitudinal vision related quality of life in patients with non-infectious uveitis

Elizabeth A Sugar; Vidya Venugopal; Jennifer E Thorne; Kevin D Frick; Gary N Holland; Robert C Wang; Almanzor Robert; Janet T Holbrook

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4131.

ARVO Annual Meeting Abstract June 2015

The global burden of potential productivity loss from uncorrected presbyopia

David A Wilson; Kevin D Frick; Kovin Shunmugam Naidoo; Brien A Holden

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2133.

ARVO Annual Meeting Abstract April 2014

Incremental Cost-Effectiveness of Fluocinolone Acetonide Implant vs Systemic Therapy for Non-infectious Intermediate, Posterior, and Pan-Uveitis

Elizabeth A Sugar; Janet T Holbrook; John H Kempen; Alyce E Burke; Lea T Drye; Jennifer E Thorne; Thomas A Louis; Douglas A Jabs; Michael M Altaweel; Kevin Frick; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5796.

ARVO Annual Meeting Abstract June 2013

Stability of the Relationship Between Self-Reported Vision Impairment and Blindness and Medical Care Expenditures Over Time

Kevin Frick; Elizabeth Wehler

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4400.

ARVO Annual Meeting Abstract June 2013

Provision of Mass Drug Administration for Trachoma Control: Cost per gain in coverage

Sheila West; Harran Mkocha; Beatriz Munoz; Kevin Frick

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4420.

ARVO Annual Meeting Abstract June 2013

Utility and Uncorrected Refractive Error

Nina Tahhan; Eric Papas; Timothy Fricke; Kevin Frick; Brien Holden

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5330.

ARVO Annual Meeting Abstract June 2013

The Association of Vision Loss with Work Status in the United States

Cheryl Sherrod; Kevin Frick; Pradeep Ramulu; Clinical/ Epidemiologic Research

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4543.

ARVO Annual Meeting Abstract June 2013

The global burden of potential productivity loss from presbyopia

Susan Joy; Kevin Frick; Kovin Naidoo; David Wilson; Brien Holden

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4545.

ARVO Annual Meeting Abstract June 2013

Health utility in the Multicenter Uveitis Steroid Treatment Trial

Elizabeth Sugar; Alyce Burke; Lea Drye; Janet Holbrook; John Kempen; Jennifer Thorne; Kevin Frick; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5934.

ARVO Annual Meeting Abstract March 2012

Reliability of Ophthalmic Utility Measures

Nina Tahhan; Eric Papas; Timothy R. Fricke; Kevin D. Frick; Brien A. Holden

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1420.

ARVO Annual Meeting Abstract March 2012

Excess Expenditures, Excess Informal Care Days, and Quality of Life Decrements Associated with Self-Reported Visual Impairment and Blindness

Kevin D. Frick; Lori L. Grover; Elizabeth Wehler

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6939.

ARVO Annual Meeting Abstract March 2012

Older Adult Access to Vision Rehabilitation Care in the U.S

Lori L. Grover; Kevin D. Frick

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4412.

Clinical and Epidemiologic Research March 2012

Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial

PDF

Kevin D. Frick; Lea T. Drye; John H. Kempen; James P. Dunn; Gary N. Holland; Paul Latkany; Narsing A. Rao; H. Nida Sen; Elizabeth A. Sugar; Jennifer E. Thorne; Robert C. Wang; Janet T. Holbrook; for the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group
TAGS: uveitis, vision, visual acuity, steroid therapy, health, health-related quality of life, eye, sf-36
Invest. Ophthalmol. Vis. Sci.. 2012; 53(3):1169-1176. https://doi.org/10.1167/iovs.11-8259

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Differences in Serious Difficulty Seeing and Utilization of Eye Exams by Sexual Orientation (2016-2020)

IMI Impact of Myopia

Trends in eyecare access and affordability: The National Health Interview Survey (NHIS) 2008–2016

Cost analysis of a school-based vision program in Baltimore, MD

Estimated global productivity loss from myopia

Overview of Surveillance Recommendations of the "Making Eye Health a Population Health Imperative: Vision for Tomorrow" Report, from the National Academies of Sciences, Engineering, and Medicine

Analysis of the cost savings from applying optical coherence tomography (OCT) to guide treatment for choroidal neovascularization

Longitudinal vision related quality of life in patients with non-infectious uveitis

The global burden of potential productivity loss from uncorrected presbyopia

Incremental Cost-Effectiveness of Fluocinolone Acetonide Implant vs Systemic Therapy for Non-infectious Intermediate, Posterior, and Pan-Uveitis

Stability of the Relationship Between Self-Reported Vision Impairment and Blindness and Medical Care Expenditures Over Time

Provision of Mass Drug Administration for Trachoma Control: Cost per gain in coverage

Utility and Uncorrected Refractive Error

The Association of Vision Loss with Work Status in the United States

The global burden of potential productivity loss from presbyopia

Health utility in the Multicenter Uveitis Steroid Treatment Trial

Reliability of Ophthalmic Utility Measures

Excess Expenditures, Excess Informal Care Days, and Quality of Life Decrements Associated with Self-Reported Visual Impairment and Blindness

Older Adult Access to Vision Rehabilitation Care in the U.S

Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial

To View More...

You must be signed into an individual account to use this feature.